Latest Conference Coverage

Ankit Jain, CEO, Co-Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions.

Ankit Jain, CEO, Co-Founder, Infinitus touches on the approach to human oversight in an effort to build trust in autonomous patient access workflows by keeping humans and AI in a continuous feedback loop.

Ankit Jain, CEO, Co-Founder, Infinitus, discusses how AI-native patient access infrastructure appears to be less about replacing care teams and more about eliminating the friction between diagnosis and therapy initiation.

Matthew Turner, President of Patient Affordability, Paysign, discusses Paysign's approach to measuring copay program value in an effort to move beyond simple redemption counts toward a more complete picture of patient adherence.

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing manufacturers toward more sophisticated, partnership-driven program designs.

Matthew Turner, President of Patient Affordability, Paysign discusses how next-generation copay assistance appears to be less about consolidating services under one vendor and more about assembling best-in-class partnerships.

New technologies are impacting the speed-to-therapy within hub services.

Manufacturers are rethinking patient assistance program architecture amid the economic pressures of the Inflation Reduction Act.

Angela Schwab, CEO at Trialynx, continues her conversation with Pharmaceutical Executive, this time detailing her experience with debuting her company at the conference.

Trialynx CEO Angela Schwab discusses where she saw AI succeeding and failing at the healthcare conference.

Immunome president and CEO Clay Siegall explains why the weeks following JP Morgan are just as important as the conference itself.

Clay Siegall, president and CEO of Immunome, discusses what he saw investors getting excited for at the annual healthcare conference.

In the final part of his conversation with Pharmaceutical Executive, Ken Keller discusses what his expectations are following the healthcare conference.

The biggest and most important takeaways from the recent JP Morgan Healthcare Conference.

Jeff Liter, CEO of Luminary Therapeutics, discusses the importance of demonstrating clinical evidence at the JP Morgan Healthcare Conference.

Ken Keller, Daiichi Sankyo’s head of global oncology and CEO of US operations, discusses the importance of bringing quality data to the JP Morgan Healthcare Conference.

Daiichi Sankyo’s US CEO and head of global oncology Ken Keller explains what his expectations are for JP Morgan prior to the conference.

Graham Goodrich, CCO, Apnimed, points to 2026 as a pivotal year marked by Apnimed’s planned NDA filing for AD109, the build-out of its commercial infrastructure and access strategy, and preparations for a potential FDA decision in early 2027.

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined strategy focused on sustained growth over the next decade, AbbVie highlighting continued pipeline advancements as it prepares for future revenue transitions, and Novavax detailing its shift toward a partnership-driven operating model.

Novavax entered the 2026 J.P. Morgan Healthcare Conference positioning itself as a partner-driven company focused on monetizing its Matrix-M platform through diversified royalties and disciplined cost control.

Graham Goodrich, CCO, Apnimed, positions AD109 as a long-awaited, patient-acceptable therapy for untreated sleep apnea that delivers meaningful improvements in oxygenation, daily functioning, and peace of mind.

Company executives detailed the company’s strategy for the coming year amidst a flurry of announcements.

Genmab used the 44th Annual J.P. Morgan Healthcare Conference to reposition itself as it enters 2026 with a reshaped business model.

Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.

David Ricks detailed how the company plans to build on the success of Zepbound and Lilly Direct.

Michael O'Rourke, CEO of Re-Vana Therapeutics, touches on Re-Vana's transition from an academic spinout to a fully established biotech, marked by team expansion, facility growth, and validation of its sustained-delivery platform.

Bayer’s strategic portfolio refresh, late-stage pipeline progress, and operational efficiency positions the company for long-term growth across cardiovascular, oncology, and women’s health.

CEO Rob Davis details specific funding forecasts for the company beyond Keytruda.

Regeneron CEO Len Schleifer highlighted the company’s science-driven platform approach, strong 2025 commercial performance, and a robust pipeline across multiple therapeutic areas poised for regulatory filings, clinical milestones, and new product launches.

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, and continued cost discipline.